All     Test   
HKMPDC SARS-CoV-2 (COVID-19) Real-time RT- CR測試成功取得歐盟”歐洲議會和理事會關於體外診斷醫療設備的認證 CE-IVD”

College of American Pathologists,

EMQN, European Molecular Genetics Quality Network,

EMQN, European Molecular Genetics Quality Network,

HKMPDC SARS-CoV-2 (COVID-19) Real-time RT-PCR Assay received CE-IVD marking
according to the European Standards: Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices

HKMPDC is offering COVID-19 (2019-nCoV) real-time RT-PCR test using CE-IVD approved assay.
HKMPDC to provide PIK3CA hotspot mutation test for the first FDA approved treatment Piqray (alpelisib) for patient with PIK3CA mutation in HR+/HER2 advanced breast cancer using either tissue or blood sample.
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
The First US FDA Approved Non-invasive (BLOOD) EGFR Mutation Test for Lung Cancer Targeted Therapy Using Liquid Biopsy
HKMPDC the first ISO 15189 accredited Molecular Diagnostic Laboratory to provide FDA approved liquid biopsy EGFR test.

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
HKMPDC The First HOKLAS ISO 15189:2012 Accredited Laboratory for Molecular Oncology Testing.
ISO 15189 Accredited Hereditary Cancer Genetic Test:
ISO 15189 Accredited Cancer Biomarker Testing for Precision Medicine (Targeted Therapy):

FoundationOne test, Foundation Medicine

Harmony Prenatal Test in Hong Kong

Counsyl, DNS screening